Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patientsAlexandra Samsen, Hartmut Juhl, Eike von Leitner et al.|Oncotarget|2018Cited by 4
Abstract 913: Differences in basal isoform phosphorylation of signaling proteins between normal and tumor tissue in different cancer types detected by the NanoPro™1000 technologyFlorian T. Unger, Kerstin A. David, Jana Krueger et al.|Cancer Research|2014Cited by 0
Abstract 2408: Comparison of ERK, AKT and MEK isoform phosphorylations between primary and corresponding metastatic colorectal carcinoma lesions using the NanoPro1000 technology.Florian T. Unger, Kerstin A. David, Jana Krueger et al.|Cancer Research|2013Cited by 0
Abstract A40: Detection of Erk1/2, Mek1/2, and Akt isoform phosphorylation in tumors of 115 patients with different cancer types using the NanoPro™1000 technology.Florian T. Unger, Kerstin A. David, Jana Krüger et al.|Molecular Cancer Therapeutics|2013Cited by 0
NanoPro 1000 analysis of Erk1/2, Mek1/2, and Akt isoform phosphorylation in clinical samples from 115 patients.Florian T. Unger, Kerstin A. David, Jana Krueger et al.|Journal of Clinical Oncology|2014Cited by 0